BlackRock’s Liminatus Pharma LIMN Stock Holding History

BlackRock’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.48K	Buy	934 +928	+15,467%	+$4.68K	﹤0.01%	5635
2026 Q2	$35	Sell	6 -259	-98%	-$2.24K	﹤0.01%	5646
2026 Q1	$2.28K	Hold	265	–	–	﹤0.01%	5512
2025 Q4	$8.09K	Hold	265	–	–	﹤0.01%	5303
2025 Q3	$22.1K	Hold	265	–	–	﹤0.01%	5132
2025 Q2	$148K	Buy	+265	New	+$149K	﹤0.01%	4741

Other funds holding LIMN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

BlackRock's LIMN Position: Q3 2026 in Review

BlackRock increased its Liminatus Pharma (LIMN) stake by 15,467% in Q3 2026, buying an estimated $4.68K and bringing the position to 934 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #5635.

BlackRock first reported a position in LIMN in Q2 2025 and has held it in 6 quarters since. The position peaked at $148K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

BlackRock held 934 shares of Liminatus Pharma worth $3.48K as of Q3 2026.
BlackRock bought 928 Liminatus Pharma shares in Q3 2026, an estimated $4.68K.
Liminatus Pharma made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5635 holding.
BlackRock first reported a position in Liminatus Pharma in Q2 2025 and has held it in 6 quarters since.
BlackRock's Liminatus Pharma position peaked at $148K in Q2 2025.
9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.